Trastuzumab
Progesterone-Receptor Negative Breast Cancer
Explore 18 assets in Progesterone-Receptor Negative Breast Cancer →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Jules Bordet Institute
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04675827CT.gov De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade | — | Terminated | — | — | — |
NCT02774681CT.gov Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Progesterone-Receptor Negative Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Trastuzumab (this asset) | Jules Bordet Institute | P2 | B · 57 |
| Carboplatin | Northwestern University | P3 | BBB |
| Epirubicin | Massachusetts General Hospital | P2 | BB |
| Pembrolizumab | Massachusetts General Hospital | P2 | BB |
| Cyclophosphamide | Massachusetts General Hospital | P3 | BB |
| Capecitabine | M.D. Anderson Cancer Center | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | University of Washington | P3 | BB |
| Adriamycin | Roswell Park Cancer Institute | P3 | BB |
| Ixabepilone | National Cancer Institute (NCI) | P3 | B |
+42 more in the Progesterone-Receptor Negative Breast Cancer cohort
Other indications for Trastuzumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P4 | BBB · 76 |
| Inflammatory Breast Carcinoma | — | P3 | BBB · 74 |
| HER2 Positive Breast Carcinoma | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Trastuzumab in Progesterone-Receptor Negative Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/trastuzumab-progesterone-receptor-negative-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →